Takeda Pharmaceuticals Invests In Seqster 

By Dan Anderson ● Feb 17, 2020
  • Seqster — an SaaS-based technology platform enabling person-centric health data management — announced recently that it received funding from Takeda Pharmaceuticals

Seqster — an award-winning SaaS-based technology platform enabling person-centric health data management — announced recently that it received funding from Takeda Pharmaceuticals. Takeda Pharmaceuticals is an R&D-driven biopharmaceutical leader headquartered in Japan. And the funds invested in Seqster will be used to accelerate the adoption of Seqster’s interoperability technology for enhancing clinical trials, patient engagement, and outcomes.

“We are thrilled to have Takeda Pharmaceuticals as a strategic investor sharing our vision and mission of putting patients at the center of all of their health data and making health data into medicine,” said Seqster CEO and co-founder Ardy Arianpour. “We have created a unique data-sharing environment that retrieves, parses and harmonizes multi-dimensional data sets thereby accelerating the entire drug development process with high fidelity data hosted within a HIPAA-compliant and HiTrust data schema. Seqster provides clinical trial participants a secure platform to consent and share their data with investigators and study personnel in real-time creating a longitudinal health record that facilitates patient clinical trial onboarding, monitoring and post-trial follow-ups.”

Seqster recently released Seqster Version 5.0, which creates a personalized patient experience, delivers improved patient outcomes, and generates actionable data. Plus it is supported by a platform designed for patients and their needs, featuring one core patient engagement platform that brings disparate data sets together in a common form.

“Our funding of Seqster is a cornerstone of our digital health strategy, and further enables us to serve our patient community by advancing the deployment of innovative technology solutions,” added Bruce Meadows, Head of Investments at Takeda Digital Ventures. “Seqster’s technology is a very unique platform that addresses interoperability on not only a nationwide scale but also globally. Interoperability is one of the biggest barriers to applying precision medicine to clinical trials and patient engagement.”

Seqster enables organizations to drive efficient healthcare via comprehensive medical records (EHR), individual genomic profiles (DNA), and personal health device data. And for the first time, users are able to create their own Matched and longitudinal health data profile across all of their US-based healthcare data sources through person-centric interoperability. The Seqster platform currently connects users to more than 3,000 healthcare providers and over 100,000 hospitals and clinics nationwide.

“We couldn’t be more excited to be contributing to empowering patients to access their health data and share it on their own terms,” explained Janine Kopp, Venture Associate at Takeda Digital Ventures.